Paysign 2025 Q3 Earnings Record Net Income Surges 54.2%

Generated by AI AgentDaily EarningsReviewed byTianhao Xu
Saturday, Nov 15, 2025 7:39 am ET1min read
Aime RobotAime Summary

-

Paysign
(PAYS) Q3 revenue surged 41.6% to $21.6M, driven by $12.86M in plasma industry revenue and $7.92M from pharma affordability programs.

- Net income hit a 16-year high of $2.22M (+54.2% YoY), with EPS rising 33.3% to $0.04 due to operational efficiencies and expanded offerings.

- Despite strong results, shares fell 4.84% post-earnings, with 9.72%

MTD
decline, while 2025 guidance was raised to $80.5–$81.5M.

- CEO highlighted new 30,000-sq-ft contact center and Q3 share repurchases, signaling confidence in long-term growth through plasma donor programs and affordability solutions.

Paysign (PAYS) delivered a standout quarter, with revenue and net income both surpassing expectations. The company raised full-year revenue guidance to $80.5–$81.5 million, reflecting robust performance in pharma patient affordability programs and plasma operations.

Revenue

Plasma industry revenue led the way with $12.86 million, while pharma patient affordability programs contributed $7.92 million. Additional revenue streams added $815,396, bringing the total to $21.60 million—a 41.6% year-over-year increase.

Earnings/Net Income

Paysign’s EPS rose 33.3% to $0.04, and net income hit a 16-year high of $2.22 million, up 54.2% from the prior year. This marks a significant milestone in profitability, driven by operational efficiencies and expanded program offerings.

Post-Earnings Price Action Review

Following the earnings report, Paysign’s stock dropped 4.84% in the latest trading day, though it edged up 0.79% for the week. The stock has declined 9.72% month-to-date, reflecting mixed investor sentiment despite strong financial results.

CEO Commentary

Mark Newcomer, President and CEO, highlighted record revenue and adjusted EBITDA, emphasizing growth in patient affordability programs and plasma operations. He noted the opening of a new support center and optimism about expanding high-value offerings.

Guidance

Paysign raised 2025 revenue guidance to $80.5–$81.5 million, with pharma patient affordability expected to comprise 41% of total revenue. Net income is projected at $7.0–$8.0 million, or $0.12–$0.13 per diluted share, while Adjusted EBITDA is forecast at $19.0–$20.0 million.

Additional News

Paysign recently opened a 30,000-square-foot customer service contact center, quadrupling support capacity to meet rising demand. The company also repurchased 100,000 shares during Q3, signaling confidence in its long-term value. Additionally, management reiterated a focus on expanding plasma donor compensation programs and pharmaceutical affordability solutions, positioning the company for sustained growth in 2026.

Comments



Add a public comment...
No comments

No comments yet